Published • loading... • Updated
Abivax inflammatory bowel drug shows benefit in relapsed and non-responding patients
The update showed 37.2% of previously nonresponsive patients reached remission after 44 weeks, while expanded safety data found cancer rates in line with expectations.
- Abivax shares jumped 25% on Tuesday after the Paris-based biotech released fresh Phase 3 ABTECT maintenance trial results showing malignancies within expected background rates for its lead drug, obefazimod.
- Investor sentiment had soured after earlier maintenance trial data revealed cancer cases among patients taking the highest dose, causing shares to crash around 44% on June 2.
- The latest results showed 37.2% of patients who initially failed to respond achieved clinical remission after 44 weeks, while 34.5% showed bowel-lining healing and 45.5% regained remission at the 50 mg dose.
- Jefferies analysts called the update "supportive," but questioned whether findings satisfy investors, citing "cancer risk may be tough to discount, sparse catalyst path, cash needs, catalyst path ex-M&A."
- Chief Executive Marc de Garidel affirmed Abivax remains on track to submit a New Drug Application later this year, while the company evaluates the drug for Crohn disease with mid-2027 trial results expected.
Insights by Ground AI
12 Articles
12 Articles
Abivax Soars 27% After Trial Update Eases Fears About Cancer
Abivax SA soared as much as 27% after a clinical-trial update soothed some investors’ concerns about whether cancer could be a potential side effect of the biotech’s most promising experimental drug.
·New York, United States
Read Full Article
Abivax inflammatory bowel drug shows benefit in relapsed and non-responding patients
Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, sending U.S.-listed shares of the Paris-based company soaring 26.4% in extended trading.
·New York, United States
Read Full Article
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources12
Leaning Left2Leaning Right0Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
